| Year |
Citation |
Score |
| 2006 |
Liby K, Rendi M, Suh N, Royce DB, Risingsong R, Williams CR, Lamph W, Labrie F, Krajewski S, Xu X, Kim H, Brown P, Sporn MB. The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5902-9. PMID 17020999 DOI: 10.1158/1078-0432.Ccr-06-1119 |
0.425 |
|
| 2004 |
Rendi MH, Suh N, Lamph WW, Krajewski S, Reed JC, Heyman RA, Berchuck A, Liby K, Risingsong R, Royce DB, Williams CR, Sporn MB. The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer. Cancer Research. 64: 3566-71. PMID 15150113 DOI: 10.1158/0008-5472.Can-04-0234 |
0.448 |
|
| 2004 |
Dragnev KH, Pitha-Rowe I, Ma Y, Petty WJ, Sekula D, Murphy B, Rendi M, Suh N, Desai NB, Sporn MB, Freemantle SJ, Dmitrovsky E. Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 2570-7. PMID 15073138 DOI: 10.1158/1078-0432.Ccr-03-0271 |
0.38 |
|
| 2002 |
Honda T, Honda Y, Favaloro FG, Gribble GW, Suh N, Place AE, Rendi MH, Sporn MB. A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production. Bioorganic & Medicinal Chemistry Letters. 12: 1027-30. PMID 11909709 DOI: 10.1016/S0960-894X(02)00105-1 |
0.376 |
|
| Show low-probability matches. |